ライフサイエンスコーパス: ELISA

1 ELISA analysis showed that 25 of the insect cell-express

2 ELISA measurements in human serum also indicate distinct

3 ELISA of casein and alpha-lactalbumin showed a decrease

4 ELISA screening of soluble VEGFR2 in the blood of LZTR1-

5 ELISA sensitivity for IgA or IgG detection was 67.9% (95

6 ELISA testing for dengue was positive in two additional

7 ELISA, but not qPCR, identified age to be a significant

8 ELISAs targeting RBD and S1 protein of SARS-CoV-2 are pr

9 eas DIF- multisite ocular MMP differed for 1 ELISA and 3 of 7 test combinations.

10 ike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted follo

11 nduced geometric mean anti-spike IgG (63,160 ELISA units) and neutralization (3906) responses that ex

12 no false positives, with the exceptions of 2 ELISAs.

13 C4 levels were measured using Abcam ELISA assays.

14 In addition, ELISA analyses were used to determine the IgG titres aga

15 easured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples.

16 ell; based on our in-house developed NPM-ALK ELISA; LOD of 40 pM) as compared to the ubiquitous beta-

17 solubilisation, CMV IgG is determined by an ELISA assay specifically adapted to cope with low IgG co

18 s are in agreement with those provided by an ELISA kit and allow discrimination between positive and

19 To address this question we developed an ELISA to assess serum levels of IgG, IgM, and IgA autoan

20 ng B. microti antibody containing sera in an ELISA.

21 tion clinics at these five centres, using an ELISA-based point-of care test (HemoTypeSC).

22 ng ustekinumab levels were measured using an ELISA.

23 Ts by myeloperoxidase-DNA complexes using an ELISA.

24 um levels were measured by ImmunoCAP 250 and ELISA.

25 Secretomic analysis and ELISA uncovered dysregulated collagen degradation regula

26 etion was measured by multiplex analysis and ELISA.

27 , and synthetic activation by gene array and ELISA.

28 PLA(2)R1 antibody levels by western blot and ELISA.

29 on of urinary volatile organic compounds and ELISA assays showed that the loading-conditioned urine r

30 rther analysis with qPCR, flow cytometry and ELISA experiments revealed that GM-CSF blockage in monoc

31 Here, using flow cytometry and ELISA we show that GM-CSF induces an inflammatory profil

32 ative PCR, intracellular flow cytometry, and ELISA.

33 s were measured by multiplex immunoassay and ELISA in serum samples and periodontal tissues.

34 sequencing, and performed immunoblotting and ELISA.

35 ogenic substrate assays, immunoblotting, and ELISA, we analyzed expression media, cell lysates, and p

36 cell lysis, conventional off-line lysis and ELISA confirmed accuracy.

37 antitative LC-MS/MS, untargeted LC-MS/MS and ELISA.

38 eatment using SDS-PAGE, FTIR, UPLC-MS/MS and ELISA.

39 Using multiplexed immunoassay panels and ELISA, 26 biomarkers were assessed in plasma.

40 therapy reduces cytokine storm in plasma and ELISA demonstrates reduced levels of matrix metalloprote

41 udy highlights that combined use of qPCR and ELISA for FFV may enhance estimates of the true prevalen

42 The stability and ELISA performance of Gel-BSA-OHG was evaluated in compar

43 stress markers by multiplex assay system and ELISA assay, respectively.

44 lts indicate that individual variability and ELISA specificity for inactive aggregates are key factor

45 by conventional NS1 antigen and IgM antibody ELISA kits.

46 munoglobulin (Ig) M, IgA, and total antibody ELISAs increased in sensitivity to >80% between days 6 a

47 bulk cell populations by techniques such as ELISA or immunoblotting.

48 -dependent, diagnostic applications, such as ELISA tests based on the peroxidase-H(2)O(2)-ABTS system

49 of a CRP enzyme-linked immunosorbent assay (ELISA) (Eurolyser) in comparison to that of a reference

50 luding an enzyme linked immunosorbent assay (ELISA) and a Luminex-based microsphere immunoassay.

51 s such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay.

52 assay is enzyme-linked immunosorbent assay (ELISA) based and can measure competition and blocking of

53 standard enzyme-linked immunosorbent assay (ELISA) directly from unprocessed samples.

54 bodies by enzyme-linked immunosorbent assay (ELISA) for 126 study participants.

55 Enzyme-linked immunosorbent assay (ELISA) is a widely used technique for detecting and quan

56 The enzyme-linked immunosorbent assay (ELISA) is commonly used throughout production to monitor

57 Enzyme-linked immunosorbent assay (ELISA) is the gold standard method for protein biomarker

58 2 protein enzyme-linked immunosorbent assay (ELISA) on patient serum at baseline before therapy start

59 ction via enzyme-linked immunosorbent assay (ELISA) or V-Plex, and mRNA levels were assessed via reve

60 Moreover, enzyme-linked immunosorbent assay (ELISA) tests were negative for mackerel parvalbumin and

61 aditional enzyme-linked immunosorbent assay (ELISA) to establish a nanozyme-based ELISA towards alpha

62 l million enzyme-linked immunosorbent assay (ELISA) units.

63 uorescent enzyme-linked immunosorbent assay (ELISA) using a fluorescence substrate.

64 tigens by enzyme-linked immunosorbent assay (ELISA) using sera from naive rabbits and rabbits with S.

65 This enzyme-linked immunosorbent assay (ELISA) was based on spotting different antibodies in a c

66 A novel enzyme-linked immunosorbent assay (ELISA) was developed for the detection of ethylene thiou

67 firmed by enzyme-linked immunosorbent assay (ELISA), demonstrating that tissue binding of QX-RBD is d

68 rmined by enzyme-linked immunosorbent assay (ELISA), for Human Abeta and soluble APP, and Western ana

69 sessed by enzyme-linked immunosorbent assay (ELISA), histology, and immunohistochemistry.

70 C-MS) and Enzyme-Linked Immunosorbent Assay (ELISA), including higher sensitivity and repeatability,

71 itored by enzyme-linked immunosorbent assay (ELISA), liquid chromatography coupled to mass spectromet

72 cultures, Enzyme linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and gene microa

73 a simple enzyme-linked immunosorbent assay (ELISA)-based assay that uses the temperature-dependent l

74 apo M by Enzyme-Linked ImmunoSorbent Assay (ELISA).

75 red by an enzyme-linked immunosorbent assay (ELISA).

76 means of enzyme-linked immunosorbent assay (ELISA).

77 mpared to enzyme-linked immunosorbent assay (ELISA).

78 uch as an enzyme-linked immunosorbent assay (ELISA).

79 mpetitive enzyme-linked immunosorbent assay (ELISA).

80 omics and enzyme-linked immunosorbent assay (ELISA).

81 mpetitive enzyme-linked immunosorbent assay (ELISA).

82 s well as enzyme-linked-immunosorbent-assay (ELISA).

83 ponse (in enzyme-linked immunosorbent assay [ELISA] units).

84 hemistry, immunofluorescence, Luminex assay, ELISA, UniCAP, fluorescence-activated cell sorting, and

85 FID) and enzyme linked immunosorbent assays (ELISA) are being adapted for the detection of this deadl

86 mmercial enzyme-linked immunosorbent assays (ELISAs) and 2 rapid tests in 77 patients with polymerase

87 in-house enzyme-linked immunosorbent assays (ELISAs) and correlated serological measurements with NAb

88 lfate in enzyme-linked immunosorbent assays (ELISAs) and depended on heparan sulfate for efficient ce

89 Enzyme-linked immunosorbent assays (ELISAs) for BP180 and BP230 (MBL International), immunog

90 mmercial enzyme-linked immunosorbent assays (ELISAs) is widely used for routine surveillance in comme

91 esins in enzyme-linked immunosorbent assays (ELISAs) revealed several reactivity patterns, including

92 vailable enzyme-linked immunosorbent assays (ELISAs) targeting the nucleoprotein (N), the S1 domain o

93 ected by enzyme-linked immunosorbent assays (ELISAs).

94 specific enzyme-linked immunosorbent assays (ELISAs).

95 sandwich enzyme-linked immunosorbent assays (ELISAs).

96 ") using enzyme-linked immunosorbent assays (ELISAs).

97 proteins, using a high-throughput, automated ELISA-based screening platform employing a pooled-protei

98 were measured using a commercially available ELISA kit.

99 as quantified using a commercially available ELISA kit.

100 gG antibodies using a commercially available ELISA.

101 o 383-fold lower than commercially available ELISA.

102 the only two FFV diagnostic tests available-ELISA and qPCR-as well as the prevalence of FFV in a lar

103 Here, we used a cell-based ELISA (CBE) assay to evaluate each component individuall

104 assay (ELISA) to establish a nanozyme-based ELISA towards alpha-lactalbumin (allergenic protein).

105 hed by the integration of the nanozyme-based ELISA with a smartphone.

106 ly, the scope of Gel-BSA-OHG substrate-based ELISA for clinical application was demonstrated by valid

107 pike glycoprotein and nucleocapsid (N)-based ELISAs not only showed high specificity and sensitivity

108 An excellent agreement was found between ELISA measurements and fluorescence polarization results

109 Western blots, ELISAs, and confocal immunocytochemistry showed EsMIF wa

110 ange were tested for total IgG and IgG1-4 by ELISA, anti-HLA-total IgG, IgG3 and IgG4, and donor-spec

111 onist osteoprotegerin (OPG) were analyzed by ELISA, quantitative polymerase chain reaction (qPCR), an

112 TREM-1 and PGLYRP1 levels were analyzed by ELISA.

113 Biomarker levels in GCF were analyzed by ELISA.

114 ype I collagen (NTx) levels were analyzed by ELISA.

115 negative for EBOV-specific IgG antibodies by ELISA.

116 ue seroprevalence in the cohort, detected by ELISA, and validated by that detected by reference FRNT.

117 roborated the protein expression detected by ELISA.

118 red NPM-ALK/ beta-actin ratios determined by ELISA to those independently determined by two-dimension

119 Denaturation of Pru p 3, determined by ELISA using rabbit IgG, occurred when the protein was tr

120 to allergens and peptides were determined by ELISA, and IgG blocking was assessed by basophil activat

121 ApoA-IV serum levels were determined by ELISA.

122 LRG, IL-6 and TNF-alpha were determined by ELISA.

123 , IGF-1 and IGFBP-2 levels were evaluated by ELISA at baseline and 6-12 months after surgery.

124 using an aptamer-based platform, followed by ELISA validation in two independent cohorts comprised of

125 f phage display and binder identification by ELISA.

126 atient sera and in our mouse model of IIM by ELISA.

127 measure serological status and infection by ELISA.

128 for the diagnosis of S. aureus infection by ELISA.

129 following mRNA treatment as investigated by ELISA and western blot.

130 ed strongly with antibody levels measured by ELISA (R(2)=0.67 by Marburg VN; p<0.001).

131 , and expression of proteins was measured by ELISA and Luminex analysis.

132 fferent treatment conditions was measured by ELISA and qRT-PCR.

133 ped, while total tau (t-tau) was measured by ELISA and the presence of tau368 in tangles was evaluate

134 ncentrations of GS and GFAP were measured by ELISA in patients with NMOSD (n=39, 28 aquaporin-4 (AQP4

135 d keyhole limpet hemocyanin were measured by ELISA, and presence of autoantibody was detected by micr

136 CML and sRAGE were measured by ELISA, and the CML/sRAGE ratio was calculated.

137 Antiviral Abs were measured by ELISA.

138 factors (RFs)-IgM and -IgA were measured by ELISA.

139 levels were assayed in the culture medium by ELISA.

140 cation Cohort, Maputo Region, Mozambique) by ELISA and nephelometry techniques.

141 omplexes in normal human serum and plasma by ELISA using Abs specific for ficolin-2 and ficolin-3.

142 y (AP) regulatory factors were quantified by ELISA (n = 181) and examined via transcriptomics data fr

143 Plasma FKBPL was quantified by ELISA cross-sectionally in 353 adults, consisting of 234

144 erial and viral pathogens were quantified by ELISA in 68 uninfected controls, 62 individuals with lat

145 22 and IL17a cytokine release, quantified by ELISA.

146 pecific antibodies and cellular responses by ELISA, basophil activation, splenocyte proliferations, a

147 and chemokines were examined in the sera by ELISA and in skin biopsies by immunohistochemistry and i

148 bacterial antigens were measured in sera by ELISA from five patient cohorts (n = 214).

149 irst extracellular loop of DRD2 was shown by ELISA.

150 were quantified from culture supernatants by ELISA.

151 against multiple strains of RV A viruses by ELISA, including strains A1A, A1B, A15, A16 and A49.

152 oughput screening on the basis of an in-cell ELISA assay.

153 tion with established CA125 chemiluminiscent ELISA with P-value<0.0001.

154 aged red wine, while whereas the commercial ELISA kit was instead unable to detect egg white in the

155 In competition ELISA, IgG1 binding to Mal d 1 in post-rMal d 1 SLIT ser

156 ogesterone antibodies involved a competitive ELISA format (optical) which confirmed recognition of th

157 y were to develop and validate a competitive ELISA targeting a specific neo-epitope of COL6alpha3 and

158 cow milk protein allergy using a competitive ELISA.

159 analyzed using a newly developed competitive ELISA for IgG, IgM, and IgA autoantibodies to FceRIalpha

160 In comparison to conventional ELISA-based sandwich immunoassays on microtiter plates,

161 roduction was measured using flow cytometry, ELISA, RNA in situ hybridization and quantitative real t

162 3 days after challenge using flow cytometry, ELISA, RNA sequencing, and mass spectrometry.Measurement

163 Flow cytometry, ELISAs, cocultures, intracellular staining and suppressi

164 Baseline DBS ELISA assay CRP measures yielded a mean positive bias of

165 sion revealed good agreement between the DBS ELISA method and reference assay data, with baseline dat

166 llent correlation with an in-house-developed ELISA (r = 0.973).

167 A newly developed ELISA showed that domain-specific PLA(2)R1 antibody leve

168 ere performed using conventional and digital ELISA, as well as Luminex.

169 Finally, the combination of digital ELISA and transcriptional analysis showed that LTBI dono

170 s Single Molecule Arrays (Simoa), or digital ELISA, have made significant advances in sensitivity, th

171 cell adhesion molecule 1 expression; and (e) ELISA for cytokines and chemokines measurement.

172 re than 30-fold better than that of enhanced ELISA.

173 y being used in conjunction with established ELISA techniques to provide rapid adaptability to increa

174 developed novel, to our knowledge, flexible ELISA-based assays for specific detection of human SARS-

175 n = 22), and pAD/MCI with SCeVD (n = 16) for ELISA quantification of cargo proteins.

176 Unlike traditional antibody printing for ELISA that prints a capture antibody specific to a targe

177 trated the importance of protein targets for ELISA.

178 Compared with FRNT, ELISA had high sensitivity and specificity (>90%), but t

179 d not interfere with IgG, IgA, or hemoglobin ELISA.

180 SF concentrations of NPTX2 using an in-house ELISA, and NPTX1 and NPTX receptor (NPTXR) by Western bl

181 the performance of current M. hyopneumoniae ELISAs and an understanding of their use in surveillance

182 In study 1, 6 commercial M. hyopneumoniae ELISAs were compared using serum samples from 8-week-old

183 next-generation sequencing, and specific Ig-ELISA were used to characterize the cells functionally.

184 o-E6-TMPRSS2 cells; a commercial IgG and IgA ELISA to detect the spike (S) protein S1 domain (EUROIMM

185 ely identified as seropositive by dengue IgG ELISA and then vaccinated might be at risk of developing

186 articipants and batch tested by indirect IgG ELISA and FRNT.

187 % of the nAb-negative samples were still IgG ELISA positive.

188 vaccination, but the sensitivity of the IgG ELISA was much lower in this group than in those with a

189 were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a mulip

190 2, 2017, and we tested each sample with IgG ELISA.

191 Using nAb titers as the reference, the IgG ELISAs confirmed 95%-98% of the nAb-positive samples, bu

192 l (mean age 3.7 months) with Immundiagnostik ELISA.

193 compared to a commercial enzyme immunoassay (ELISA) and a recently described novel surrogate virus ne

194 cell death were evaluated by immunoblotting, ELISA, and cell death assays, respectively.

195 Here, using immunoblotting, ELISA, and surface plasmon resonance analysis, we report

196 tion (LIPS) and enzyme-linked immunosorbent (ELISA) immunoassays.

197 1 was competed with rMal d 1 and rBet v 1 in ELISA.

198 The protein's IgE reactivity was analyzed in ELISA experiments, and cross-reactivity with allergens o

199 serum or detection probes, as is required in ELISA-based approaches.

200 r functional validation experiments included ELISA measurement of human samples, murine left anterior

201 f the fluid manipulations for 96 independent ELISA reactions can be achieved simultaneously without a

202 8E-phage) was further applied in an indirect ELISA to the analysis of 50 commercial food samples.

203 ate the performance of a dengue IgG indirect ELISA in determining dengue seroprevalence in a cohort o

204 main (EUROIMMUN); IgA, IgG, and IgM indirect ELISAs to detect the full-length S protein or S receptor

205 We developed an inhibition ELISA with high specificity and sensitivity that is appl

206 ized donors in direct binding and inhibition ELISA.

207 gambiense inhibition ELISA (g-iELISA) is based on the principle that binding

208 A RVFV inhibition ELISA was used to screen 977 cattle, 1,549 sheep and 523

209 In this work, a protein-protein interaction ELISA revealed the interaction of PscN with a wide range

210 We establish the epitope-loss ELISA as a useful tool for studies of filovirus entry, e

211 ase chain reaction (PCR) and/or IgM Zika MAC-ELISA.

212 ell activation was determined by serum Mcpt1 ELISA in response to ovalbumin challenge.

213 nge, 0.01-0.06) than natural Ara h 2 (median ELISA OD, 0.99; interquartile range, 0.90-1.03; P < .01)

214 ayed significantly lower IgE binding (median ELISA OD, 0.03; interquartile range, 0.01-0.06) than nat

215 Here, we present a portable microfluidic ELISA technology for rapid (15 min), quantitative, and s

216 ngs, immunofluorescence confocal microscopy, ELISA, and aptamer proteomics were used to identify and

217 Ag/BSA as a nanomagnetic bead, and microwell ELISA plate, MTP-p53Ag/BSA were compared.

218 For the microwell ELISA plate assay, the LoD was 42.0 pg mL(-1) and the li

219 is quicker than 3 h needed for the microwell ELISA plate assay.

220 The new small molecule-ELISA methodology was tested using a panel of binders sp

221 Small molecule-ELISA procedures are particularly useful in the context

222 as analyzed for cytokine levels by multiplex ELISA.

223 in, we present a highly scalable multiplexed ELISA that achieves a similar level of performance to co

224 thus to further develop the double-nanobody ELISA for various analytes.

225 The streptavidin-bridged double-nanobody ELISA was then successfully applied to tests for recover

226 ficant risk factor, whereas neither qPCR nor ELISA identified sex to be a risk factor.

227 We evaluated the diagnostic agreement of ELISA and qPCR, and whether differences in their diagnos

228 Analysis of ELISA performance at various cutoffs found that the manu

229 One of the main drawbacks of ELISA is the involvement of multiple washing steps that

230 IgE binding was tested by means of ELISA with sera from 48 Ara h 2-sensitized patients with

231 bit significant biological activity based on ELISA studies, indicating that singlet oxygenation could

232 o compared the magnitude of these effects on ELISA results to get closer to the question of choosing

233 dies (enzyme-linked immunosorbent assay, or "ELISA"), to small molecule ligands, using fluorescein co

234 rt that commercially available G-CSF and PEG ELISA detection kits have different capacities to detect

235 In study 2, the 3 best-performing ELISAs from study 1 were compared using serum samples ge

236 re antibody-negative by the serum anti-PLA2R ELISA diagnostic test.

237 d the allergens was analyzed by quantitative ELISA using sera from 18 subjects with a proven almond a

238 n cumin and garlic, focusing on quantitative ELISA.

239 Quantitative ELISAs employing the absorbance detection method were de

240 se transcription polymerase chain reaction), ELISA, co-IP, immunostaining, knockdown and overexpressi

241 esult (2.5 h compared to 4-5 h for a regular ELISA) make the FO-SPR immunoassay a powerful assay for

242 Sandwich ELISA and its variants accomplish the capture and detect

243 FAIRS probes are composed of a sandwich ELISA antibody pair that is conjugated with two fluoroge

244 tor-binding domain, including an Ag sandwich ELISA relevant for large population screening and three

245 h 2 and Ara h 6 were determined by sandwich ELISA and SDS-PAGE, and the allergenicities of treated p

246 The double monoclonal sandwich ELISA was applied to quantify absorbed Ara h 2 and 6, an

247 The resulting sandwich ELISA using a capture nanobody (A9, 1.25 mug/mL) after p

248 tors in the GCF were quantitated by sandwich ELISAs and Multiplex assay, respectively.

249 uent development of double-nanobody sandwich ELISAs.

250 alactan-protein (LM2) epitopes, and sandwich-ELISA evidence indicates that, in wheat particularly, th

251 l biomarkers validated by aptamer screening, ELISA, and immunofluorescence microscopy.

252 We developed a highly sensitive ELISA to measure Hsp70:CHIP-dependent nNOS ubiquitinatio

253 While both tests had similar sensitivity, ELISA had higher specificity.

254 th them, we developed sensitive and specific ELISAs for these PSA molecular forms and measured them i

255 assays and are consistent with gold standard ELISA results.

256 es were consistent when compared to standard ELISA test results showing a strong correlation between

257 were assessed using an in-house standardised ELISA, a multiplex immunoassay, and a live severe acute

258 SA and characterized by competition studies, ELISAs and immunoblotting.

259 Our results suggest ELISA and qPCR did not have strong diagnostic agreement,

260 l of performance to commercial single-target ELISA kits as well as shorter assay time, less consumpti

261 ng (BOP), and interleukin-1beta were tested (ELISA) at baseline, 2 weeks, and 6 and 12 months.

262 The ELISA (LOD = 8 pg/mL) showed excellent performance in re

263 These results were corroborated by the ELISA analysis.

264 closely correlated to those measured by the ELISA technique.

265 sensitivity, accuracy, and precision in the ELISA analysis of 8-OHdG.

266 However, sensitivity of the ELISA was poor (77.1%) among children with immunity to j

267 as dengue seronegative or seropositive, the ELISA (with a 0.9 index value cutoff) showed 95.2% sensi

268 Compared to the ELISA assay commonly used to quantitate CPS type-specifi

269 high protein content and was compared to the ELISA technique.

270 ne plate and assayed this molecule using the ELISA technique.

271 t five primary health-care centres using the ELISA-based point-of-care test.

272 , but Ara h 2 could not be detected with the ELISA.

273 The specificities of the ELISAs were 83% (IgA), 98% (IgG), and 97% (IgM and total

274 While the ELISAs showed sensitivities of 88.4% for RBD, 89.3% for

275 This ELISA is enabled by a novel microscale fluid manipulatio

276 dy specific to a target of interest, in this ELISA we printed unique "anchor" antibodies at the well

277 Even though ELISA is the official detection method for such residues

278 31.53-38.92), considering 4, 55 and 18 TLC, ELISA and HPLC-based studies (including 354, 9224 and 26

279 ty in the radioimmunoassay and drug-tolerant ELISA were associated with lower median ustekinumab leve

280 using the radioimmunoassay and drug-tolerant ELISA, respectively.

281 nsitive radioimmunoassay and a drug-tolerant ELISA.

282 makes customizable multiplex ultrasensitive ELISA available to laboratories without access to the pr

283 However, scaling up ELISA for multiplexed biomarker analysis is not a trivia

284 Using ELISA tests, coating several SARS-CoV-2 proteins produce

285 Using ELISA, flow cytometry, immunoprecipitation, mass spectro

286 Using ELISA, we quantified an average of 1100, 6200 and 2500 r

287 seropositivity (Adv36 + ) was assessed using ELISA.

288 d after 24 hours, 48 hours, and 7 days using ELISA.

289 trol- and CO(2) -RWE were investigated using ELISA and untargeted metabolomics.

290 Ab titers were measured using ELISA in healthy women (n = 105; born into life study) a

291 GPTL5, HsCRP, and Ox-LDL were measured using ELISA.

292 mune mediators' levels were quantified using ELISA.

293 g antibodies levels to SACOL0688 in SF using ELISA or LFA provides a tool for the sensitive and speci

294 GRFT loading and release were determined via ELISA, showing that NP-EF composites achieved high GRFT

295 al IgG and IgM Ab levels were determined via ELISA.

296 Tissue antibody levels were quantified via ELISA and immunohistochemistry and were correlated with

297 ptide enzyme-linked immunosorbent assay (VP2-ELISA) was optimized using experimental and reference an

298 The VP2-ELISA is universal and simple and provided sensitive (99

299 antigenicity post plasma treatment, whereas ELISA of beta-lactoglobulin showed an increase in antige

300 Of the 11 sera that were false positive with ELISA, seven samples (63.6%) were seropositive for Zika